Arteris, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
10b5-1 plans:
On February 19, 2026, Paul Alpern, Vice President and General Counsel, terminated a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 114,151 shares of the Company’s common stock until August 31, 2026.
On February 23, 2026, Paul Alpern, Vice President and General Counsel, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 106,084 shares of the Company’s common stock until May 31, 2027.
On March 3, 2026, Nicholas B. Hawkins, Chief Financial Officer, cancelled a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 97,092 shares of the Company’s common stock until August 31, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.